Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In a phase 1 trial, JX-594 injection into hepatocellular carcinoma (HCC)...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Heo, Jeong, Breitbach, Caroline J, Moon, Anne, Kim, Chang Won, Patt, Rick, Kim, Mi Kyung, Lee, Yu Kyung, Oh, Sung Yong, Woo, Hyun Young, Parato, Kelley, Rintoul, Julia, Falls, Theresa, Hickman, Theresa, Rhee, Byung-Geon, Bell, John C, Kirn, David H, Hwang, Tae-Ho
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2011
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3129795/
https://ncbi.nlm.nih.gov/pubmed/21427706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2011.39
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi